ECONOMIC EVALUATION OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED RENAL-CELL CARCINOMA IN JAPAN

被引：0
|
作者：
Maeda, T. [1 ]
Morimoto, K. [2 ]
Mo, X. [3 ]
Moriwaki, K. [4 ]
Shimozuma, K. [5 ]
机构：
[1] Keio Univ, Fujisawa, Kanagawa, Japan
[2] Kyoto Univ, Kyoto, Japan
[3] Ritsumeikan Univ, Osaka 27, Japan
[4] Ritsumeikan Univ, Kyoto 26, Japan
[5] Ritsumeikan Univ, Kusatsu, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC280
引用
收藏
页码：S188 / S189
页数：2
相关论文
共 50 条
  • [21] Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
    Bedke, Jens
    Stenzl, Arnulf
    [J]. EUROPEAN UROLOGY, 2016, 69 (03) : 538 - 539
  • [22] Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma
    Mulders, Peter F. A.
    [J]. EUROPEAN UROLOGY, 2016, 69 (04) : 753 - 754
  • [23] Nivolumab plus cabozantinib for advanced renal cell carcinoma
    Benjamin, David J.
    Nolla, Kyle
    Cella, David
    [J]. FUTURE ONCOLOGY, 2022, 18 (39) : 4351 - 4359
  • [24] Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab
    Nakayama, Takayuki
    Takeshita, Hideki
    Kagawa, Makoto
    Washino, Satoshi
    Shirotake, Suguru
    Miura, Yuji
    Hyodo, Yoji
    Izumi, Keita
    Inoue, Masaharu
    Matsuoka, Yoh
    Miyagawa, Tomoaki
    Oyama, Masafumi
    Saito, Kazutaka
    Kawakami, Satoru
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [25] Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
    Shirotake, Suguru
    Miyama, Y. U.
    Baba, Yasutaka
    Tajima, Hiroyuki
    Okada, Yoshitaka
    Nakazawa, Ken
    Usami, Yoko
    Yasuda, Masanori
    Igarashi, Daisuke
    Kaneko, G. O.
    Kanao, Kent
    Oyama, Masafumi
    Nishimoto, Koshiro
    [J]. ANTICANCER RESEARCH, 2022, 42 (05) : 2727 - 2735
  • [26] Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma
    Kobayashi, Y.
    Arai, H.
    Honda, M.
    [J]. CURRENT ONCOLOGY, 2020, 27 (04) : 225 - 228
  • [27] NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma
    Adler, Amanda I.
    Brooke, Adam
    Elsada, Ahmed
    Landells, Linda
    [J]. LANCET ONCOLOGY, 2019, 20 (07): : 904 - 905
  • [28] Advanced Renal Cell Carcinoma: Combination of Nivolumab and Ipilimumab versus Sunitinib
    Lorenz, Judith
    [J]. AKTUELLE UROLOGIE, 2019, 50 (02) : 136 - 136
  • [29] MEDROXYPROGESTERONE PLUS TAMOXIFEN FOR ADVANCED RENAL-CELL CARCINOMA
    FUKS, JZ
    VANECHO, DA
    AISNER, J
    OSTROW, S
    WIERNIK, PH
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 154 - 154
  • [30] Nivolumab Plus Ipilimumab with Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma
    Soulen, Michael C.
    Haas, Naomi B.
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2023, 34 (06) : 1089 - +
12345